Inventor
George D. Hartman
Inventor
Lansdale, PA, US
Overview
Patents· 179 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds41%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
A61KPreparations for medical, dental or toiletry purposes16%
C07CAcyclic or carbocyclic compounds6%
C12NMicroorganisms or enzymes4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
Y02PClimate change mitigation technologies in the production or processing of goods1%
C07KPeptides1%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture1%
C12RIndexing scheme associated with subclasses c12c - c12q, relating to microorganisms1%
PatentTitleYear
11,129,834Combinations and methods comprising a capsid assembly inhibitor202110,987,359Oxadiazepinone derivatives and methods of treating hepatitis B infections202110,975,077Diazepinone derivatives and their use in the treatment of hepatitis B infections202110,632,112Combination therapy for treatment of HBV infections202010,556,904Derivatives and methods of treating hepatitis B infections202010,544,141Derivatives and methods of treating hepatitis B infections202010,537,580Azocane and azonane derivatives and methods of treating hepatitis B infections202010,538,519Derivatives and methods of treating hepatitis B infections202010,441,589Combinations and methods comprising a capsid assembly inhibitor201910,392,349Azepane derivatives and methods of treating hepatitis B infections201910,364,228Azepane derivatives and methods of treating hepatitis B infections201910,213,420Combination therapy for treatment of HBV infections201910,196,376Hepatitis B antiviral agents201910,189,835Derivatives and methods of treating hepatitis B infections201910,093,669Derivatives and methods of treating hepatitis B infections201810,077,264Derivatives and methods of treating hepatitis B infections201810,077,239Crystalline forms of a hepatitis B antiviral agent20189,890,161'Derivatives and methods of treating hepatitis B infections'20189,884,831'Azocane and azonane derivatives and methods of treating hepatitis B infections'20189,873,671Azepane derivatives and methods of treating hepatitis B infections20189,758,489'Azepane derivatives and methods of treating hepatitis B infections'20179,751,857'Hepatitis B antiviral agents'20179,676,747'Hepatitis B antiviral agents'20179,579,313'Hepatitis B antiviral agents'20179,550,779'Derivatives and methods of treating hepatitis B infections'20179,527,845'Derivatives and methods of treating hepatitis B infections'20169,518,057'Derivatives and methods of treating hepatitis B infections'20169,505,722'Azepane derivatives and methods of treating hepatitis B infections'20169,400,280'Piperidine derivatives and methods of treating hepatitis B infections'20169,339,510'Azepane derivatives and methods of treating hepatitis B infections'20169,205,079'Hepatitis B antiviral agents'20159,181,288'Azepane derivatives and methods of treating hepatitis B infections'20159,169,212'Azepane derivatives and methods of treating hepatitis B infections'20159,115,113'Azepane derivatives and methods of treating hepatitis B infections'20159,066,932'Hepatitis B antiviral agents'20159,061,008'Hepatitis B antiviral agents'20158,993,771'Hepatitis B antiviral agents'20158,629,274'Hepatitis B antiviral agents'20147,825,135'Heteroaryl piperidine glycine transporter inhibitors'20107,745,639'Mitotic kinesin inhibitors'20107,732,472'Mitotic kinesin inhibitors'20107,718,687'Prodrugs of mitotic kinesin inhibitors'20107,632,839'Mitotic kinesin inhibitors'20097,632,833'Mitotic kinesin inhibitors'20097,625,936'Mitotic kinesin inhibitors'20097,625,912'Mitotic kinesin inhibitors'20097,618,971'Mitotic kinesin inhibitors'20097,553,838'Mitotic kinesin inhibitors'20097,465,746'Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP'20087,378,411'Substituted thienopyrimidinones as a mitotic kinesin inhibitor'20087,348,440'Mitotic kinesin inhibitors'20087,329,762'Prodrugs of mitotic kinesin inhibitors'20087,265,134'Tyrosine kinase inhibitors'20077,262,187'Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor'20077,262,186'Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor'20077,244,723'Substituted furopyrimidinones as a mitotic kinesin inhibitors'20077,235,580'Mitotic kinesin inhibitors'20077,186,723'Tyrosine kinase inhibitors'20077,169,788'Tyrosine kinase inhibitors'20077,115,597'Tyrosine kinase inhibitors'20067,109,204'Tyrosine kinase inhibitors'20067,109,191'Benzazepinone alpha vintegrin receptor antagonists'20066,958,340'Tyrosine kinase inhibitors'20056,927,293'Tyrosine kinase inhibitors'20056,875,767'(5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors'20056,794,393'Tyrosine kinase inhibitors'20046,784,190'Integrin receptor antagonists'20046,586,423'Tyrosine kinase inhibitors'20036,586,424'Tyrosine kinase inhibitors'20036,420,382'Tyrosine kinase inhibitors'20026,410,526'v integrin receptor antagonists'20026,376,496'Inhibitors of prenyl-protein transferase'20026,358,956'Inhibitors of prenyl-protein transferase'20026,358,970'Integrin receptor antagonists'20026,313,138'Tyrosine kinase inhibitors'20016,306,874'Tyrosine kinase inhibitors'20016,297,249'Integrin receptor antagonists'20016,294,549'Method for eliciting an .alpha.v.beta.5 or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonizing effect'20016,211,184'Integrin antagonists'20016,117,842'Fibrinogen receptor antagonists'20006,090,948'Inhibitors of farnesyl-protein transferase'20006,066,738'Inhibitors of farnesyl-protein transferase'20006,048,861'Integrin receptor antagonists'20006,040,311'Integrin receptor antagonists'20006,040,317'Sulfonamide fibrinogen receptor antagonists'20006,028,201'Inhibitors of farnesyl-protein transferase'2000RE036520'HMG-CoA reductase inhibitors'2000RE036481'HMG-CoA reductase inhibitors'20005,990,107'Fibrinogen receptor antagonist prodrugs'19995,981,584'Fibrinogen receptor antagonist prodrugs'19995,981,562'Inhibitors of farnesyl-protein transferase'19995,981,546'Integrin antagonists'19995,968,965'Inhibitors of farnesyl-protein transferase'19995,952,341'Integrin antagonists'19995,952,306'Integrin receptor antagonists'19995,945,545'Fibrinogen receptor antagonists'19995,932,582'Fibrinogen receptor antagonist prodrugs'19995,929,120'Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption'19995,925,655'.alpha..sub.v .beta..sub.3 antagonists'19995,919,792'Integrin antagonists'19995,914,341'Inhibitors of farnesyl-protein transferase'19995,900,414'Methods for administering integrin receptor antagonists'19995,889,023'Fibrinogen receptor antagonist'19995,880,136'Sulfonamide fibrinogen receptor antagonists'19995,856,326'Inhibitors of farnesyl-protein transferase'19995,854,245'Fibrinogen receptor antagonists'19985,852,045'Fibrinogen receptor antagonists'19985,814,643'Sulfonamide fibrinogen receptor antagonists'19985,786,373'Fibrinogen receptor antagonists'19985,780,480'Fibrinogen receptor antagonists'19985,741,796'Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption'19985,721,253'Fibrinogen receptor antagonists'19985,719,162'Fibrinogen receptor antagonists'19985,719,144'Fibrinogen receptor antagonists'19985,665,723'Fibrinogen receptor antagonists'19975,658,929'Sulfonamide fibrinogen receptor antagonists'19975,648,368'Fibrinogen receptor antagonists'19975,646,000'Compounds and methods for identifying activated platelets'19975,559,127'Fibrinogen receptor antagonists'19965,525,617'Fibrinogen receptor antagonists'19965,494,921'Fibrinogen receptor antagonists'19965,455,243'Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets'19955,416,099'Fibrinogen receptor antagonists'19955,397,791'Fibrinogen receptor antagonists'19955,358,956'Fibrinogen receptor antagonists'19945,334,596'Fibrinogen receptor antagonists'19945,321,034'Fibrinogen receptor antagonists'19945,294,616'Fibrinogen receptor antagonists'19945,292,756'Novel sulfonamide fibrinogen receptor antagonists'19945,281,585'Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets'19945,272,158'Fibrinogen receptor antagonists'19935,264,420'Fibrinogen receptor antagonists'19935,227,490'Fibrinogen receptor antagonists'19935,217,994'Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives'19935,204,350'Method of inhibiting osteoclast-mediated bone resorption by administration of N-heterocyclicalkyl-substituted phenyl derivatives'19935,130,306'5-Oxygenated HMG-COA reductase inhibitors'19925,116,870'HMG-CoA reductase inhibitors'19925,098,931'7-substituted HMG-CoA reductase inhibitors'19924,963,538'5-oxygenated HMG-CoA reductase inhibitors'19904,943,588'Prodrugs of antihypercholesterolemic compounds'19904,940,727'Novel HMG-CoA reductase inhibitors'19904,929,549'5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors'19904,914,111'4-Benzylthiophene (or furan)-2-sulfonamides as antiglaucoma agents'19904,897,402'5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors'19904,894,390'Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents'19904,876,271'Substituted thieno[3,2-b]thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors'19894,857,546'Novel HMG-CoA reductase inhibitors'19894,847,289'Thiophene sulfonamide antiglaucoma agents'19894,837,205'Prodrugs of antihypercholesterolemic compounds'19894,808,718'Fused polycyclic and bridged compounds useful as calcium channel blockers'19894,806,562'Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents'19894,798,831'Substituted thieno[2,3-B]furan-2-sulfonamides as antiglaucoma agents'19894,788,203'Cyclized N-substituted-tetrahydropyridine compounds, useful in the treatment of cardiovascular disorders'19884,751,231'Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents'19884,735,956'Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers'19884,736,064'Prodrugs of antihypercholesterolemic compounds'19884,721,708'Cyclized N-substituted-tetrahydropyridine compounds and cardiovascular use'19884,709,035'2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to radiation therapy'19874,678,806'Prodrugs of antihypercholesterolemic compounds'19874,670,443'Benzo(f)isoquinoline compounds useful as calcium entry blockers'19874,609,659'2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to radiation therapy'19864,599,341'Substituted and bridged pyridines useful as calcium channel blockers'19864,593,033'Substituted indeno[2,1-c] pyridines useful as calcium channel blockers'19864,587,253'Bridged pyridine compounds useful as calcium channel blockers and analgesics'19864,563,451'Quinazolino-1,4-benzodiazepin-5,13-diones'19864,548,941'1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers'19854,532,237'Substituted and bridged pyridines useful as calcium channel blockers'19854,443,457'Aminocrot onylpyridine N-oxides useful as adjuncts to radiation therapy'19844,443,458'Aminocrotonyl 3,5-dinitropyridine useful as adjuncts to radiation therapy'19844,438,266'Triazolopyrazinamines useful as adjuncts to radiation therapy'19844,435,400'Amino and alkylaminoalkenoate ester derivatives of aminochloronitropyrazine'19844,418,062'Amino derivatives of chloro nitro amino pyrazines useful as adjuncts to radiation therapy'19834,416,882'Di(alkylamino) derivatives of chloronitropyrazines useful as adjuncts to radiation therapy'19834,414,215'N-Acyl derivatives of 6-alkylamino 5-chloro-3-nitropyrazinamines for radiation therapy'1983RE031429'Process for preparation of 9-(dihalobenzyl)adenines'19834,127,721'Derivatives of thiadiazolo[3,4-d]pyrimidine'19784,098,787'Process for preparation of 9-(dihalobenzyl) adenines'19784,021,438'Novel process for the preparation of thiazoles'19774,010,173'Synthesis of 4-cyanothiazoles'1977Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1977–2010Patents assigned to MERCK & CO INC (138)· patent assignee history
1977Based in Plainsboro, NJ, US· patent location history
1978–2021Based in Lansdale, PA, US· patent location history
1994–2017Based in Landsdale, PA, US· patent location history
2010Patents assigned to MERCK SHARP & DOHME (4)· patent assignee history
2014–2021Patents assigned to NOVIRA THERAPEUTICS INC (38)· patent assignee history
2014Patents assigned to FLORES OSVALDO A (1)· patent assignee history
2014Based in Radnor, PA, US· patent location history
2015–2017Based in Doylestown, PA, US· patent location history
2019–2021Patents assigned to JANSSEN SCIENCES IRELAND UNLIMITED CO (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MERCK & CO INC | 138 | 1977–2010 |
| NOVIRA THERAPEUTICS INC | 38 | 2014–2021 |
| MERCK SHARP & DOHME | 4 | 2010 |
| JANSSEN SCIENCES IRELAND UNLIMITED CO | 2 | 2019–2021 |
| FLORES OSVALDO A | 1 | 2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Lansdale, Pennsylvania, US | 166 | 1978–2021 |
| Landsdale, Pennsylvania, US | 7 | 1994–2017 |
| Doylestown, Pennsylvania, US | 3 | 2015–2017 |
| Plainsboro, New Jersey, US | 2 | 1977 |
| Radnor, Pennsylvania, US | 1 | 2014 |